Last reviewed · How we verify
AP707
At a glance
| Generic name | AP707 |
|---|---|
| Also known as | THC |
| Sponsor | CannaXan GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy (PHASE3)
- Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain (PHASE3)
- Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis (PHASE3)
- Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis (PHASE3)
- Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy (PHASE3)
- Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy (PHASE3)
- Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain (PHASE3)
- Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |